Details of the Drug Combination

General Information of Drug Combination (ID: DCK8MBI)

• Drug Combination Name: Ampicillin + Gentamicin
• Indication: Premature Birth; Status: Phase 3 [1]
• Component Drugs:
  Ampicillin (DMHWE7P): Small molecular drug
  Gentamicin (DMKINJO): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Ampicillin

Disease Entry	ICD 11	Status	REF
Acute epiglottitis	N.A.	Approved	[2]
Acute gonococcal cervicitis	N.A.	Approved	[2]
Acute otitis media	AB00	Approved	[2]
Bacillary dysentery	1A02	Approved	[2]
Bacteremia	1A73	Approved	[2]
Bacterial endocarditis	N.A.	Approved	[2]
Bacterial infection	1A00-1C4Z	Approved	[3]
Cholangitis	N.A.	Approved	[2]
Chorioamnionitis	N.A.	Approved	[2]
Dysentery	N.A.	Approved	[2]
Escherichia coli meningitis	N.A.	Approved	[2]
Meningococcal meningitis	N.A.	Approved	[2]
Peritonitis	N.A.	Approved	[2]
Pneumococcal meningitis	N.A.	Approved	[2]
Staphylococcal pneumonia	N.A.	Approved	[2]
Staphylococcus aureus infection	N.A.	Approved	[2]
Streptococcal pneumonia	N.A.	Approved	[2]
Urinary tract infection	GC08	Approved	[2]
Paratyphoid fever	N.A.	Investigative	[2]
Pelvic inflammatory disease	GA05	Investigative	[2]
Sinusitis	CA0A.Z	Investigative	[2]

Ampicillin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial Penicillin binding protein (Bact PBP)	TTJP4SM	NOUNIPROTAC	Binder	[7]

Ampicillin Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[8]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[9]
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[10]

Ampicillin Interacts with 13 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
N-acylhomoserine lactone acylase (lacA)	DEIU0XN	A0A0A1VBK6_9BURK	Metabolism	[11]
Beta-lactamase (blaB)	DET9I1W	BLAC_BACUN	Metabolism	[12]
AmpC beta-lactamase (ampC)	DERI7LO	A0A0H3KQ39_BURM1	Metabolism	[13]
Beta-lactamase (blaB)	DE3FVRW	BLA2_BAC17	Metabolism	[14]
Beta-lactamase (blaB)	DETDS7E	A0A2S0LB67_9FLAO	Metabolism	[14]
Beta-lactamase (blaB)	DEQX0DG	Q8RIK5_FUSNN	Metabolism	[14]
Beta-lactamase (blaB)	DEC7JEF	A0A1S1G219_9NEIS	Metabolism	[14]
Beta-lactamase (blaB)	DEXB2A9	A0A379CPC3_PLESH	Metabolism	[15]
Beta-lactamase (blaB)	DEBKS91	A0A1B1FBM9_ACIBA	Metabolism	[16]
Beta-lactamase (blaB)	DEWMGC3	A0A2U9SV73_9BURK	Metabolism	[14]
Beta-lactamase (blaB)	DEWYT5M	D4HFC4_CUTAS	Metabolism	[14]
Beta-lactamase (blaB)	DE52KD0	Q6EZ46_RALPI	Metabolism	[14]
Beta-lactamase (blaB)	DEG5Y4W	A0A344X3A2_STASP	Metabolism	[14]

Ampicillin Interacts with 77 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Decreases Activity	[17]
Phospholemman (FXYD1)	OTNKT6GP	PLM_HUMAN	Increases Expression	[6]
Interferon-related developmental regulator 1 (IFRD1)	OT4SQMLQ	IFRD1_HUMAN	Decreases Expression	[6]
CCN family member 1 (CCN1)	OTKJBEMD	CCN1_HUMAN	Increases Expression	[6]
Calmegin (CLGN)	OTEWVFQV	CLGN_HUMAN	Decreases Expression	[6]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Decreases Expression	[6]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Decreases Expression	[6]
Dickkopf-related protein 1 (DKK1)	OTRDLUSP	DKK1_HUMAN	Increases Expression	[6]
Chloride intracellular channel protein 3 (CLIC3)	OT5KUZ3A	CLIC3_HUMAN	Increases Expression	[6]
Ceruloplasmin (CP)	OTM8JE4Y	CERU_HUMAN	Increases Expression	[6]
Metalloproteinase inhibitor 1 (TIMP1)	OTOXC51H	TIMP1_HUMAN	Decreases Expression	[6]
Cystatin-A (CSTA)	OT1K68KE	CYTA_HUMAN	Decreases Expression	[6]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Expression	[6]
Arginase-1 (ARG1)	OTHZITAM	ARGI1_HUMAN	Increases Expression	[6]
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Increases Expression	[6]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Decreases Expression	[6]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)	OT2HZK5M	GTR3_HUMAN	Increases Expression	[6]
Creatine kinase B-type (CKB)	OTUCKOTT	KCRB_HUMAN	Increases Expression	[6]
Pyruvate kinase PKM (PKM)	OTLHHMC2	KPYM_HUMAN	Increases Expression	[6]
Transcription factor JunD (JUND)	OTNKACJD	JUND_HUMAN	Increases Expression	[6]
Insulin-like growth factor-binding protein 3 (IGFBP3)	OTIX63TX	IBP3_HUMAN	Increases Expression	[6]
Gastricsin (PGC)	OTQRITKI	PEPC_HUMAN	Increases Expression	[6]
Parathymosin (PTMS)	OT9PS4Q0	PTMS_HUMAN	Increases Expression	[6]
Calreticulin (CALR)	OTYD2TR1	CALR_HUMAN	Increases Expression	[6]
Protein-lysine 6-oxidase (LOX)	OT1C2HIU	LYOX_HUMAN	Increases Expression	[6]
Dual specificity protein phosphatase 1 (DUSP1)	OTN6BR75	DUS1_HUMAN	Increases Expression	[6]
Sodium- and chloride-dependent creatine transporter 1 (SLC6A8)	OT88C8JA	SC6A8_HUMAN	Increases Expression	[6]
Glutamate--cysteine ligase catalytic subunit (GCLC)	OTESDI4D	GSH1_HUMAN	Decreases Expression	[6]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Decreases Expression	[6]
Rho GDP-dissociation inhibitor 1 (ARHGDIA)	OTEXWJDO	GDIR1_HUMAN	Increases Expression	[6]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Decreases Expression	[6]
Myc-associated zinc finger protein (MAZ)	OTEHKN1M	MAZ_HUMAN	Increases Expression	[6]
Tropomyosin alpha-4 chain (TPM4)	OTN4YLYR	TPM4_HUMAN	Increases Expression	[6]
Transgelin (TAGLN)	OTAEZ0KP	TAGL_HUMAN	Increases Expression	[6]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Decreases Expression	[6]
Prostaglandin reductase 1 (PTGR1)	OTMAR351	PTGR1_HUMAN	Decreases Expression	[6]
Ankyrin repeat domain-containing protein 1 (ANKRD1)	OTHJ7JV9	ANKR1_HUMAN	Increases Expression	[6]
Na(+)/H(+) exchange regulatory cofactor NHE-RF2 (NHERF2)	OTRHB9SR	NHRF2_HUMAN	Increases Expression	[6]
Carbonic anhydrase 9 (CA9)	OTNA51XT	CAH9_HUMAN	Increases Expression	[6]
Dual specificity protein phosphatase 7 (DUSP7)	OT6Z5AHP	DUS7_HUMAN	Increases Expression	[6]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)	OT25JBA3	F263_HUMAN	Increases Expression	[6]
Filamin A-interacting protein 1-like (FILIP1L)	OTPY8IMS	FIL1L_HUMAN	Increases Expression	[6]
Angiomotin (AMOT)	OTWHDG9B	AMOT_HUMAN	Increases Expression	[6]
Glycerol-3-phosphate acyltransferase 3 (GPAT3)	OTJUGPK0	GPAT3_HUMAN	Decreases Expression	[6]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3)	OTDMU3GP	CR3L3_HUMAN	Decreases Expression	[6]
Leukocyte-associated immunoglobulin-like receptor 2 (LAIR2)	OTKCADXC	LAIR2_HUMAN	Decreases Expression	[6]
Sterile alpha motif domain-containing protein 1 (SAMD1)	OT2LK4JW	SAMD1_HUMAN	Increases Expression	[6]
Lipocalin-15 (LCN15)	OT9YXMIL	LCN15_HUMAN	Increases Expression	[6]
Protein MTSS 2 (MTSS2)	OTKMNSBF	MTSS2_HUMAN	Increases Expression	[6]
Carbohydrate sulfotransferase 15 (CHST15)	OTNTM2SP	CHSTF_HUMAN	Increases Expression	[6]
Solute carrier family 22 member 15 (SLC22A15)	OT60WAAI	S22AF_HUMAN	Decreases Expression	[6]
BPI fold-containing family B member 2 (BPIFB2)	OTXWTWQ9	BPIB2_HUMAN	Increases Expression	[6]
Arrestin domain-containing protein 4 (ARRDC4)	OTINJ0FX	ARRD4_HUMAN	Decreases Expression	[6]
Phospholipid phosphatase-related protein type 1 (PLPPR1)	OT4A560N	PLPR1_HUMAN	Increases Expression	[6]
Jun dimerization protein 2 (JDP2)	OTW35WKX	JDP2_HUMAN	Decreases Expression	[6]
Aquaporin-3 (AQP3)	OT2J7JPD	AQP3_HUMAN	Decreases Expression	[6]
Arrestin domain-containing protein 3 (ARRDC3)	OTAKW7R9	ARRD3_HUMAN	Decreases Expression	[6]
Small integral membrane protein 14 (SMIM14)	OT47IF19	SIM14_HUMAN	Decreases Expression	[6]
Sulfiredoxin-1 (SRXN1)	OTYDBO4L	SRXN1_HUMAN	Decreases Expression	[6]
Homeobox protein Hox-D1 (HOXD1)	OTN4V9ZF	HXD1_HUMAN	Increases Expression	[6]
Regulator of cell cycle RGCC (RGCC)	OTYJMLWM	RGCC_HUMAN	Increases Expression	[6]
Serine/threonine-protein kinase Sgk2 (SGK2)	OTCTVSHF	SGK2_HUMAN	Decreases Expression	[6]
Endothelial cell-specific molecule 1 (ESM1)	OT331Y8V	ESM1_HUMAN	Decreases Expression	[6]
]-phosphatase 2, mitochondrial (PDP2)	OTADNMGK	PDP2_HUMAN	Increases Expression	[6]
Cell cycle progression protein 1 (CCPG1)	OT0IHDKL	CCPG1_HUMAN	Decreases Expression	[6]
Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) (SLC6A14)	OTN51IPT	S6A14_HUMAN	Increases Expression	[6]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Decreases Expression	[6]
Proliferation-associated protein 2G4 (PA2G4)	OT7IG7HT	PA2G4_HUMAN	Increases Expression	[6]
Pirin (PIR)	OT8ALXHU	PIR_HUMAN	Increases Expression	[18]
Tripartite motif-containing protein 16 (TRIM16)	OTLRXYOZ	TRI16_HUMAN	Increases Expression	[18]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[18]
Liver carboxylesterase 1 (CES1)	OT9L0LR8	EST1_HUMAN	Increases Expression	[18]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[19]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[19]
Tumor necrosis factor receptor superfamily member 5 (CD40)	OT5YU2XB	TNR5_HUMAN	Increases Expression	[19]
Excitatory amino acid transporter 2 (SLC1A2)	OTEP3QGN	EAA2_HUMAN	Increases Expression	[20]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Increases Transport	[21]

Indication(s) of Gentamicin

Disease Entry	ICD 11	Status	REF
Bacteremia	1A73	Approved	[4]
Bacterial infection	1A00-1C4Z	Approved	[5]
Blepharoconjunctivitis	N.A.	Approved	[4]
Cholangitis	N.A.	Approved	[4]
Dacryocystitis	N.A.	Approved	[4]
Demodex blepharitis	1G07	Approved	[4]
Folliculitis	N.A.	Approved	[4]
Neonatal sepsis	N.A.	Approved	[4]
Paronychia	1F23.13	Approved	[4]
Peritonitis	N.A.	Approved	[4]
Pseudomonas aeruginosa infectious disease	N.A.	Approved	[4]

Gentamicin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial 30S ribosomal RNA (Bact 30S rRNA)	TTOVFH2	NOUNIPROTAC	Modulator	[24]

Gentamicin Interacts with 6 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Aminoglycoside O-phosphotransferase (aphA6)	DEWPAJD	KKA6_ACIBA	Metabolism	[25]
Aminoglycoside phosphotransferase (aph-Ib)	DE5WGIM	A0A075C7U3_CAMJU	Metabolism	[26]
Kanamycin/gentamycin-resistance enzyme (aacA)	DECXWN8	J3S7E2_CAMCO	Metabolism	[26]
Endoglucanase Y (EGY)	DE2M583	A0A256VAC0_LACRE	Metabolism	[27]
Endoglucanase Y (EGY)	DE2AZTG	A0A256VAC0_LACRE	Metabolism	[27]
Aminoglycoside 6'-N-acetyltransferase (aacA)	DE48UAX	C5MQW3_KLEPO	Metabolism	[28]

Gentamicin Interacts with 53 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Alpha-L-iduronidase (IDUA)	OTTQQ7FN	IDUA_HUMAN	Increases Expression	[29]
Tripeptidyl-peptidase 1 (TPP1)	OT2LQ771	TPP1_HUMAN	Increases Expression	[30]
Exocyst complex component 3 (EXOC3)	OT8N3306	EXOC3_HUMAN	Increases Expression	[31]
Slit homolog 1 protein (SLIT1)	OT35RBNT	SLIT1_HUMAN	Decreases Expression	[23]
Coagulation factor VIII (F8)	OTH6XHDU	FA8_HUMAN	Increases Expression	[32]
Coagulation factor IX (F9)	OTT0CX3Q	FA9_HUMAN	Increases Expression	[32]
Cystatin-C (CST3)	OTNZ6AO4	CYTC_HUMAN	Increases Expression	[31]
Pro-epidermal growth factor (EGF)	OTANRJ0L	EGF_HUMAN	Decreases Expression	[31]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Expression	[33]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[31]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Increases Expression	[31]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[22]
Heat shock 70 kDa protein 1A (HSPA1A)	OTKGIE76	HS71A_HUMAN	Increases Expression	[34]
Dystrophin (DMD)	OTD21T5J	DMD_HUMAN	Increases Expression	[35]
Xaa-Pro dipeptidase (PEPD)	OT3LFY7S	PEPD_HUMAN	Decreases Activity	[36]
Cystic fibrosis transmembrane conductance regulator (CFTR)	OT6B22QH	CFTR_HUMAN	Increases Activity	[37]
Aminopeptidase N (ANPEP)	OTP3WYFD	AMPN_HUMAN	Increases Secretion	[38]
Methylmalonyl-CoA mutase, mitochondrial (MMUT)	OTBBBV70	MUTA_HUMAN	Affects Expression	[39]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[22]
Endothelin receptor type B (EDNRB)	OTLLZV3P	EDNRB_HUMAN	Increases Expression	[23]
Insulin-like growth factor-binding protein 5 (IGFBP5)	OTRE5V0C	IBP5_HUMAN	Decreases Expression	[23]
HLA class I histocompatibility antigen, alpha chain F (HLA-F)	OT76CM19	HLAF_HUMAN	Increases Expression	[23]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[31]
Leukemia inhibitory factor receptor (LIFR)	OT36W9O5	LIFR_HUMAN	Decreases Degradation	[40]
ATP-sensitive inward rectifier potassium channel 1 (KCNJ1)	OTIXCRI6	KCNJ1_HUMAN	Increases Expression	[41]
Cytosolic purine 5'-nucleotidase (NT5C2)	OTJMF66Z	5NTC_HUMAN	Increases Expression	[23]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Expression	[31]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4)	OT29B58J	KCNQ4_HUMAN	Decreases Expression	[23]
Beta-2-microglobulin (B2M)	OTDWN6NX	B2MG_HUMAN	Increases Expression	[42]
Neutrophil gelatinase-associated lipocalin (LCN2)	OTSB42BR	NGAL_HUMAN	Decreases Secretion	[43]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[31]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Increases Expression	[44]
Polycystin-2 (PKD2)	OTIXBU8H	PKD2_HUMAN	Increases Expression	[45]
Runt-related transcription factor 3 (RUNX3)	OTITK1XD	RUNX3_HUMAN	Decreases Expression	[23]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Increases Expression	[22]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Decreases Expression	[31]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Expression	[31]
Partitioning defective 3 homolog (PARD3)	OTH5BPLO	PARD3_HUMAN	Decreases Expression	[23]
GATOR1 complex protein NPRL2 (NPRL2)	OTOB10MO	NPRL2_HUMAN	Decreases Expression	[23]
Hepatitis A virus cellular receptor 1 (HAVCR1)	OT184CRZ	HAVR1_HUMAN	Increases Expression	[31]
Rho guanine nucleotide exchange factor 26 (ARHGEF26)	OTX0U8PX	ARHGQ_HUMAN	Increases Expression	[23]
G-protein coupled receptor 20 (GPR20)	OTPCR8F7	GPR20_HUMAN	Increases Expression	[23]
Polyadenylate-binding protein-interacting protein 1 (PAIP1)	OTL2F5T5	PAIP1_HUMAN	Decreases Expression	[23]
Large subunit GTPase 1 homolog (LSG1)	OTDAXJ9L	LSG1_HUMAN	Decreases Expression	[23]
Glyoxalase domain-containing protein 4 (GLOD4)	OTBJKFXA	GLOD4_HUMAN	Decreases Expression	[23]
DNA-directed DNA/RNA polymerase mu (POLM)	OT0SRIP4	DPOLM_HUMAN	Increases Expression	[23]
Ubiquitin-like-conjugating enzyme ATG3 (ATG3)	OT28VBVK	ATG3_HUMAN	Decreases Expression	[23]
Phospholipase A2 (PLA2G1B)	OT1GG9FK	PA21B_HUMAN	Increases ADR	[46]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Increases ADR	[46]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1)	OTCJ458Q	AT1A1_HUMAN	Increases ADR	[46]
Solute carrier family 22 member 2 (SLC22A2)	OTGFK1AL	S22A2_HUMAN	Increases Transport	[47]
Lysosomal Pro-X carboxypeptidase (PRCP)	OTIUY91L	PCP_HUMAN	Increases ADR	[46]
Dipeptidyl aminopeptidase-like protein 6 (DPP6)	OTWW3H0K	DPP6_HUMAN	Increases ADR	[46]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Nephrolithiasis	DCHJI8J	N. A.	Phase 1	[48]
Premature Birth of Newborn	DC7CAAS	N. A.	Phase 1	[49]

References

• [1] ClinicalTrials.gov (NCT05977400) NICU Antibiotics and Outcomes (NANO) Follow-up Study
• [2] Ampicillin FDA Label
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061936.
• [4] Gentamicin FDA Label
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2427).
• [6] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [7] Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
• [8] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [9] Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
• [10] Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
• [11] A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
• [12] Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
• [13] Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
• [14] Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
• [15] Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
• [16] Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
• [17] Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull. 2006 Aug;29(8):1559-63.
• [18] Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92.
• [19] Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
• [20] Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem. 2007 Jan 19;282(3):1727-37. doi: 10.1074/jbc.M609822200. Epub 2006 Nov 30.
• [21] Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
• [22] A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
• [23] Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
• [24] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [25] Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
• [26] Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
• [27] Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
• [28] Detection of multidrug-resistant Enterobacteriaceae isolated from river waters flowing to the Guanabara Bay and from clinical samples of hospitals in Rio de Janeiro, Brazil. Biomedica. 2019 May 1;39(s1):135-149.
• [29] Alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol. 2004 Apr 30;338(3):453-62.
• [30] Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol. 2001;5 Suppl A:57-62. doi: 10.1053/ejpn.2000.0436.
• [31] In vitro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin. J Biochem Mol Toxicol. 2018 Sep;32(9):e22189. doi: 10.1002/jbt.22189. Epub 2018 Jul 10.
• [32] Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood. 2005 Nov 1;106(9):3043-8. doi: 10.1182/blood-2005-03-1307. Epub 2005 Jul 28.
• [33] Gentamicin suppresses endotoxin-driven TNF-alpha production in human and mouse proximal tubule cells. Am J Physiol Renal Physiol. 2007 Oct;293(4):F1373-80. doi: 10.1152/ajprenal.00333.2007. Epub 2007 Aug 15.
• [34] Increased expression of heat shock protein (HSP)72 in a human proximal tubular cell line (HK-2) with gentamicin-induced injury. J Toxicol Sci. 2006 Feb;31(1):61-70. doi: 10.2131/jts.31.61.
• [35] Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 2003 May;22(1):15-21.
• [36] Melanin potentiates gentamicin-induced inhibition of collagen biosynthesis in human skin fibroblasts. Eur J Pharmacol. 2002 Jun 20;446(1-3):7-13. doi: 10.1016/s0014-2999(02)01793-4.
• [37] Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology. 2002 Jan;35(1):95-104. doi: 10.1053/jhep.2002.30423.
• [38] Investigations on the potential nephrotoxicity of cefazedone and gentamicin and of their combination, in comparison with the combination of cefazolin and cephalothin with gentamicin. Arzneimittelforschung. 1979;29(2a):449-52.
• [39] Stop codon read-through of a methylmalonic aciduria mutation. Mol Genet Metab. 2009 Aug;97(4):244-9. doi: 10.1016/j.ymgme.2009.04.004. Epub 2009 Apr 12.
• [40] In vitro readthrough of termination codons by gentamycin in the Stve-Wiedemann Syndrome. Eur J Hum Genet. 2010 Jan;18(1):130-2. doi: 10.1038/ejhg.2009.122.
• [41] Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2003 Sep;64(3):923-32. doi: 10.1046/j.1523-1755.2003.00153.x.
• [42] The absence of nephrotoxicity and differential nephrotoxicity between tobramycin and gentamicin. South Med J. 1990 Oct;83(10):1149-52. doi: 10.1097/00007611-199010000-00008.
• [43] Neutrophil gelatinase-associated lipocalin production negatively correlates with HK-2 cell impairment: Evaluation of NGAL as a marker of toxicity in HK-2 cells. Toxicol In Vitro. 2017 Mar;39:52-57. doi: 10.1016/j.tiv.2016.11.012. Epub 2016 Nov 22.
• [44] Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
• [45] Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells. FASEB J. 2004 May;18(7):884-6. doi: 10.1096/fj.03-0687fje. Epub 2004 Mar 4.
• [46] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [47] Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5573-80. doi: 10.1128/AAC.00907-16. Print 2016 Sep.
• [48] ClinicalTrials.gov (NCT02829060) Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
• [49] ClinicalTrials.gov (NCT02477423) A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome